Ananda Pharma Plc’s Post

The Death of the Strategy of Classical Chiral Switches Is an Exaggeration. “Chiral switch” is “a switch of a chiral drug to a stereoisomeric drug which comprises a switch in the status of chirality, e.g., racemate to single enantiomer, epimers to single enantiomer”. #Chiral switches of drugs are considered a strategy for the discovery and development of chiral drugs. The scenario of the classical chiral switch (previously known as a racemic switch) is a switch of a racemic drug to a single-enantiomer drug. A chiral switch of a drug is not necessarily a switch of a chiral drug that had previously been marketed, e.g., as a racemate. The chiral switches of Lipitor and Plavix operated just at the level of patents; their racemic predecessors had not been approved by drug regulators. #MarkTwain’s 1897 quote, the death of the classical chiral switches is an exaggeration. Chiral switches and racemic drugs are alive. Taking into consideration the current advances and sophistication of drug-development research and technologies, old racemic drugs should be subjected to the chiral-switch strategy, including classical chiral switches and drug repurposing/chiral-switches combinations.

"Widened Scope of Drug Repurposing/Chiral Switches, Elements of Secondary Pharmaceuticals: The Quinine/Quinidine Case" This perspective article explores drug repurposing and chiral switches, focusing on the antimalarial quinine and the antiarrhythmic quinidine. It highlights how these drugs, with histories dating back to 1638, have been repurposed for new medical uses. Drug repurposing involves finding new applications for existing drugs, while chiral switches involve converting racemates to single enantiomers or other chiral forms. The article emphasizes the potential of the 16 stereoisomers of quinine/quinidine for new therapeutic uses and calls for comprehensive research in this area. Source: D’Acquarica, I., & Agranat, I. (2023). Future Drug Discovery, 5(3). https://lnkd.in/gT3rX9Tv; https://lnkd.in/gpp6EuRM #chiral_switch #drug_repurposing #secondary_pharmaceuticals #quinine_qunidine #cinchona_alkaloids #chiralpedia

Let's delve into the fascinating world of 'heavy drugs'- drugs labelled with deuterium! These innovative pharmaceuticals involve substituting hydrogen atoms with deuterium, offering exciting possibilities in drug development. A recent study used our TRC research chemicals in developing deuterium-reinforced tricyclic antidepressants (TCAs), indicating improved efficacy and safety of TCAs and a positive clinical impact on antidepressant treatment. Read more in the European Journal of Drug Metabolism and Pharmacokinetics: https://okt.to/cJNYKz View our complete solution to your laboratory’s needs – from research, drug design and development to manufacturing and qualification. Visit lgcstandards.com #ProductCitation #antidepressants #pharma #deuterium #ResearchChemicals

The FDA has released the FY 2023 Generic Drug User Fee Amendments (GDUFA) Science and Research Report, showcasing key scientific advancements and research achievements that support the development and assessment of generic drugs. Key highlights from the FY 2023 GDUFA research report include: Support for Complex Generic Drugs: GDUFA research has played a key role in approving complex generics, such as those for alcohol use disorder and opioid dependence. Facilitating Development of Challenging Generics: By introducing new methodologies, GDUFA research enables the development of previously challenging generic drugs, increasing their availability. Public Health Benefits: Improved efficiency in generic drug development helps reduce the risk of shortages, fosters competition, and enhances patient access to essential treatments. Each year, public input assists the FDA in prioritizing generic drug science and research. In FY 2023, eight priority initiatives were identified, with the report detailing active projects and their outcomes in these areas. The FDA’s Generic Drug Science and Research Program, funded through GDUFA, is essential for providing patients with high-quality, safe, and effective generic drugs. By addressing scientific knowledge gaps and developing new methodologies, the program enables the creation of previously unfeasible generics, ensuring they meet the same rigorous standards as brand-name drugs. Read the full report to learn more about how GDUFA-funded research makes a difference in public health. Follow InviMeds Health for more updates. #FDA #GenericDrugs #GDUFA #PharmaceuticalResearch #DrugDevelopment #PublicHealth #Healthcare #Medicine #PatientCare #ScientificAdvancements #DrugApproval #Pharmacy #PharmaInnovation

The Para IV Winners and Losers – May 2024   Track the Para IV space on a regular basis through our monthly report. The report is derived from our Para IV Insights – a database that covers all the Para IV litigations since 2012, both for Synthetic and Biosimilar drugs.   The report answers the following questions for the month of May 2024:   Which are the products were new Para IV filings have happened? Which products witnessed settlements and / or judgement? What opportunities emerge for companies based on the above developments? What are the key developments in the biosimilars space? For more information on the report and database – kindly contact us. #ParaIV #USgenerics #patent #505b(2) #settlement

The FDA has released a new guidance titled 'M12 Drug Interaction Studies'. The guidance provides general recommendations on evaluating the enzyme and transporter-mediated pharmacokinetic drug-drug interaction potential for investigational drugs. - Want to learn more about how this affects your drug development process? Get in touch with a member of the team www.scendea.com/contact - #drugdevelopment #regulatoryaffairs #interactionstudies

Exciting advancements in medicine! The FDA has approved several new drugs in 2024, offering new treatments for various conditions: 💊 Leqselvi for severe alopecia areata 🧠 Kisunla for Alzheimer’s disease 🫁 Ohtuvayre for chronic obstructive pulmonary disease 🩸 Piasky for paroxysmal nocturnal hemoglobinuria These approvals highlight significant progress in drug development and potential benefits for patients. Explore the latest updates and their impacts. #HealthcareInnovation #FDAApprovals #MedicalAdvancements #Pharma #Biotech #PatientCare Read more about the latest FDA approvals here: https://lnkd.in/dG2EzrRV

Conquering the patent world of metabolic antidiabetic drugs. https://lnkd.in/e6Q3RC2B Conquering the Patent World of Metabolic Antidiabetic Drugs: The development of metabolic antidiabetic drugs plays a crucial role in treating diabetes, but securing patents for these innovative treatments involves a unique set of challenges. In this video, we dive into the patent landscape for antidiabetic medications, examining key patenting strategies and how to protect your diabetes treatment innovations. Learn about the intellectual property hurdles and how to navigate the complexities of patenting antidiabetic drugs in this rapidly evolving field. This video is a must-watch for pharmaceutical professionals, researchers, and IP experts in the diabetes and metabolic disease space. Read more on this blog: https://lnkd.in/emK7gSZc... #MetabolicAntidiabeticDrugs #Development #IntellectualProperty

📖According to a new paper just published by José Alexandre de Souza Crippa and his team in Pharmaceuticals MDPI, the global appeal of therapeutic uses of cannabidiol is growing more rapidly than the scientific evidence supporting its safety and effectiveness. 💡The timely review discusses the most solid current evidence regarding the pharmacological profile of cannabidiol, its efficacy, and safety in the context of regulation and perspectives on the development of new cannabinoid-based drugs. 👉 A must-read for all those active in or preparing to enter the exciting cannabinoid-based pharmaceuticals market. https://lnkd.in/g5TwjrUE #cannabidiol #scientificevidence #pharmainnovation #mustread

Thoughts on this? >> FDA lifts partial hold on Avidity’s myotonic dystrophy drug; Orum's IPO in South Korea >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #biotech #pharma #productmarketing